International Registry Study of Neutral Lipid Storage Disease (NLSD) / Triglyceride Deposit Cardiomyovasculopathy (TGCV) and Related Diseases
NCT ID: NCT02918032
Last Updated: 2026-02-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
120 participants
OBSERVATIONAL
2014-01-31
2028-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Physiologic Plasticity of Intramyocardial Lipid Storage
NCT01921075
Familial Partial Lipodystrophy Study
NCT02858830
Dyslipidemia International Survey-China
NCT01732952
Feasibility of Adipose Tissue Triglyceride (TG) Labelling in Familial Partial Lipodystrophy (FPLD)
NCT05996536
Abnormal Lipids - Causes and Effects
NCT02195050
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Time Perspective:This study is both Prospective (registering patients who are diagnosed with NLSD / TGCV) and Retrospective (registering only the medical record of previous patients).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
NLSD / TGCV
Patients who are diagnosed with NLSD / TGCV
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kenichi Hirano, MD, Ph.D
Role: PRINCIPAL_INVESTIGATOR
Department of Cardiovascular Medicine, Faculty of Internal Medicine, Graduate School of Osaka University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Stanford University
Stanford, California, United States
Columbia University
New York, New York, United States
University of Graz
Graz, Styria, Austria
Peking University First Hospital
Beijing, Beijing Municipality, China
Pitié-Salpêtrière Hospital
Paris, Paris, France
Ludwig-Maximilians University
Munich, Bavaria, Germany
Sapienza University of Rome
Rome, Lazio, Italy
A.C.O. San Filippo Neri Hospital
Rome, Lazio, Italy
Catholic University
Milan, Lombardy, Italy
University of Padova
Padua, Veneto, Italy
Graduate School of Osaka University
Suita, Osaka, Japan
National Center of Neurology and Psychiatry
Kodaira, Tokyo, Japan
Maastricht University
Maastricht, Limburg, Netherlands
Harefield Hospital
Harefield, London, United Kingdom
New Castle University
Newcastle upon Tyne, Tyne and Wear, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Kenichi Hirano, MD, Ph.D
Role: CONTACT
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Sean M Wu
Role: primary
Salvatore DiMauro
Role: primary
Rudolf Zechner
Role: primary
Yun Yuan
Role: primary
Pascal Laforêt
Role: primary
Karim Wahbi
Role: backup
Peter Reilich
Role: primary
Marcello Arca
Role: primary
Elena M Pennisi, MD, Ph.D.
Role: primary
Daniela Tavian, MD
Role: primary
Corrado Angelini
Role: primary
Kenichi Hirano, MD, Ph.D.
Role: primary
Ichizo Nishino
Role: primary
Matthijs Hesselink
Role: primary
Nick Banner
Role: primary
Rita Horvath
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TRICVD1315
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.